Cataracts Clinical Trial
Official title:
PROOF-OF-CONCEPT STUDY FOR NEW INTRAOCULAR LENS, MODEL C0002
Prospective, two-arm, randomized, bilateral, subject/evaluator-masked clinical study to evaluate the distance visual acuity, peripheral refractive error and functional vision of the EPV IOL compared to a standard monofocal control IOL.
Status | Recruiting |
Enrollment | 160 |
Est. completion date | April 30, 2025 |
Est. primary completion date | April 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 60 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Age of study population between 60-75 years; 2. Bilateral cataracts for which cataract extraction and posterior chamber IOL implantation have been planned for both eyes; 3. Cataractous lens changes, as demonstrated by best-corrected distance visual acuity (BCDVA) of 0.50 decimal or worse (6/12 or 20/40 Snellen) either with or without a glare source present (e.g., Brightness Acuity Tester) or with significant cataract related visual symptoms in the opinion of the investigator; 4. Potential postoperative best-corrected distance visual acuity (BCDVA) of 0.66 decimal (6/9 or 20/30 Snellen) or better; 5. Drives a car at least 1-2 times per month; 6. Corneal astigmatism: 1. Normal corneal topography 2. Predicted postoperative residual refractive cylinder based on a toric IOL calculator, taking surgically induced astigmatism (SIA) into account and using the posterior corneal astigmatism (PCA) option, must be less than 1.00 D in both eyes. 7. Clear intraocular media other than cataract in each eye; 8. Availability, willingness, sufficient cognitive awareness to comply with examination procedures; 9. Signed informed consent and HIPAA authorization or equivalent documentation necessary to comply with applicable privacy laws pertaining to medical treatment in the governing countries; 10. Ability to understand, read, and write in French. Exclusion Criteria: 1. Requiring an intraocular lens power needed to achieve emmetropia (spherical equivalent ± 0.50 D) outside the available range of +18.0 D to +30.0 D for the Model C0002 IOL or +16.5 D to +27.5 D for the Model ZCB00 IOL; 2. Pupil abnormalities (non-reactive, fixed pupils, or abnormally-shaped pupils); 3. Irregular corneal astigmatism; 4. Recent ocular trauma or ocular surgery that is not resolved/stable or may affect visual outcomes or increase risk to the subject; 5. Prior corneal refractive (LASIK, LASEK, RK, PRK, etc.) or intraocular surgery; 6. Subjects who may be expected to require retinal laser treatment during the study; 7. Corneal abnormalities such as stromal, epithelial or endothelial dystrophies that are predicted to cause visual acuity losses to a level of worse than 0.66 decimal (6/9 or 20/30 Snellen) during the study; 8. Inability to achieve keratometric corneal stability preoperatively as a result of recent contact lens usage; 9. Subjects with diagnosed degenerative visual disorders (e.g., retinal disorders such as macular degeneration) that are predicted to cause visual acuity losses to a level worse than 0.66 decimal (6/9 or 20/30 Snellen) during the study; 10. Subjects with conditions associated with increased risk of zonular rupture, including capsular or zonular abnormalities that may lead to IOL decentration or tilt, such as pseudoexfoliation, trauma, or posterior capsule defects; 11. Use of systemic or ocular medications that may affect vision; 12. Prior, current, or anticipated use during the course of the study of tamsulosin or silodosin (e.g., Flomax, Flomaxtra, Rapaflo) that may, in the opinion of the investigator, confound the outcomes or increase the risk to the subject (e.g., poor dilation or a lack of adequate iris structure to perform standard cataract surgery); 13. Inability to focus or fixate for prolonged periods of time (e.g., due to strabismus, nystagmus, etc.); 14. Poorly-controlled diabetes; 15. Acute, chronic, or uncontrolled systemic or ocular disease or illness that, in the opinion of the investigator, would increase the operative risk or confound the outcomes of the study (e.g., immunocompromised, connective tissue disease, suspected glaucoma, glaucomatous changes in the fundus or visual field, ocular inflammation, etc.); NOTE: Controlled ocular hypertension without glaucomatous changes (optic nerve cupping and visual field loss) is acceptable. 16. Neurological or neurodegenerative disorders that affect locomotion and cognitive function (e.g., Muscular disorders, Parkinson's disease, Alzheimer's disease etc.); 17. Use of mobility aids, any injury or condition that may affect walking; 18. Subject has condition(s) associated with the fluctuation of hormones that could lead to refractive changes; 19. Concurrent participation in any other clinical trial or participation within 30 days prior to the preoperative visit. |
Country | Name | City | State |
---|---|---|---|
France | Centre Hospitalier National d'Ophtalmologie | Paris | Ile-de-France |
France | Rothschild Foundation Hospital | Paris | Ile-de-France |
Lead Sponsor | Collaborator |
---|---|
Johnson & Johnson Surgical Vision, Inc. |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Postoperative Refractive Error | Ocular refractive error, including defocus and astigmatism, will be measured using an autorefractor instrument. | within 14 days of completion of 1-month follow-up | |
Primary | MONOCULAR, PHOTOPIC BCDVA AT 4 M | Distance visual acuity will be measured postoperatively at 100% contrast under photopic lighting conditions (85 cd/m2, 80-110 cd/m2 acceptable). | within 14 days of completion of 1-month follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06005675 -
User Acceptability Evaluation of Pseudophakic Patients Previously Implanted With the TECNIS Odyssey IOL
|
||
Active, not recruiting |
NCT01382641 -
Show Improved Vision With the HOYA AF-1 Aspheric Intraocular Lens After Cataract Surgery
|
Phase 4 | |
Completed |
NCT01382823 -
Laser Cataract Surgery With the Femtosecond Laser Technology
|
Phase 4 | |
Completed |
NCT05991960 -
Evaluation of Real-World Data on the Performance of the TECNIS Odyssey™ IOL
|
||
Active, not recruiting |
NCT05574959 -
Clinical Investigation of the TECNIS® Next-Generation Intraocular Lens, Model DEN00V
|
N/A | |
Completed |
NCT02492659 -
Clinical Research of Femtosecond Laser-Assisted Cataract Surgery
|
N/A | |
Completed |
NCT01279031 -
Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial
|
Phase 4 | |
Completed |
NCT01001806 -
A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification
|
Phase 4 | |
Completed |
NCT00999492 -
Selection of Aspheric Diffractive Multifocal Intraocular Lens (IOLS) Based on Corneal Wavefront
|
Phase 4 | |
Completed |
NCT01061463 -
Occupational Cataracts and Lens Opacities in Interventional Cardiology : the O'CLOC Study
|
N/A | |
Completed |
NCT01021761 -
A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification
|
Phase 4 | |
Completed |
NCT00542581 -
Acrysof Toric SN60T3corneal Astigmatism Between 0.75 and 1.00 D.
|
N/A | |
Completed |
NCT03708367 -
A Post-Market Evaluation of LipiFlow Treatment in Cataract Surgery Practice
|
N/A | |
Completed |
NCT05575063 -
Clinical Investigation of Healon EndoCoat Ophthalmic Viscosurgical Device (OVD)
|
N/A | |
Completed |
NCT05058274 -
Clinical Results of a Monofocal Aspheric Bitoric Intraocular Lens With Plate Haptics in Hyperopic Eyes (HIPER-AT-TORBI)
|
||
Completed |
NCT05053399 -
Evaluation of the TECNIS Symfony® Toric Intraocular Lens
|
N/A | |
Recruiting |
NCT02639845 -
Eye Drop Application Monitor, Pilot Study
|
N/A | |
Completed |
NCT01684007 -
A Clinical Outcome Study of Two Multifocal Intraocular Lenses (IOL) in Cataract Patients
|
N/A | |
Completed |
NCT00827073 -
Comparison of Tetracaine 0.5% and Lidocaine 2% Jelly for Topical Phacoemulsification Cataract Surgery
|
N/A | |
Completed |
NCT00405730 -
Nepafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye Drops, Solution and Placebo
|
Phase 3 |